In this subgroup, patients with a basal-like (median: 46 months) or with a HER2-enriched subtype (median: 52 months) had a worse prognosis, whereas Luminal patients with a tumor showing high L1 expressions were characterized by a longer DFS (Luminal A: 92 months, Luminal B: 75 months, p-values, HR and CI95% in Table 3, Figure 4A). The gene discussed is ERBB2; the disease is neoplasm.